IRINOTECAN MYLAN 20MG/ML INF CNC SOL 1X2ML

What is the maximum co-payment for IRINOTECAN MYLAN?

If the insurance company contributes, the maximum co-payment is 1 064,95 Kč. The maximum pharmacy price is 1 294,11 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but only during an outpatient procedure. When dispensed on prescription, the patient always pays the full price.

Does IRINOTECAN MYLAN have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

229,16 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Irinotekan je hrazen u pacientů s kolorectalm karcinomem v klinickém stadiu IV:
a) v monoterapii při rezistenci na 5-fluorouracil,
b) v kombinaci FOLFIRI
c) v kombinaci XELIRI (s kapecitabinem), u pacientů u kterých není možné zavedení centrálního katetru s port systémem a provedení aplikace kontinuální infuze 5-fluorouracilu
d) v kombinaci s anti-EGFR terapií cetuximabem či panitumumabem (tj. FOLFIRI+cetuximab/panitumumab v první nebo druhé linii, irinotekan+cetuximab ve druhé linii),
e) v kombinaci s anti-VEGF terapií bevacizumabem či afliberceptem (tj. FOLFIRI+bevacizumab v první nebo druhé linii, irinotekan+bevacizumab ve druhé linii, FOLFIRI+aflibercept ve druhé linii).

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe IRINOTECAN MYLAN?

clinical oncology, pediatric oncology and hematology, radiation oncology and oncogynecology

What is the composition of IRINOTECAN MYLAN?

Trihydrát irinotekan-hydrochloridu (20 mg), irinotekan (17,33 mg), sorbitol, kyselina mléčná, neznámá látka s kódem 10186, voda pro injekci (1 ml). More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Documents could not be found

Which medicines are similar to IRINOTECAN MYLAN?

The medicine belongs to ATC group L01CE02 – IRINOTEKAN. Medicines with the same active substance can be found here.

Who manufactures IRINOTECAN MYLAN?

VIATRIS LIMITED, Dublin (IRL)

Is the medicine in shortage?

The latest report from the manufacturer is from 23. 9. 2024. Production was terminated with effect from 1. 10. 2024. The manufacturer lists medicines with the following code as a potential substitute: